Goldman SachsGSPAST TOP PICKFeb 19, 2016Stock price when the opinion was issued
As of Jul 10, 2026. Market Open.
Different businesses. LLY is a big play in GLP-1 drugs. How will pills effect the injections business? LLY has done a good job of navigating these new pills. GS enjoys increased stock market and IPO businesses. He prefers LLY, which is tied to a secular growth trend, but GS' good times in capturing revenue in this cycle will end.
Mergers are increasing, and banks like GS makes advisory fees from them. Also, the banks have been rallying since oil slumped, and will benefit further from rising interest rates, which appears will happen later this year. Plus, hyperscalers may need to keep borrowing money to keep competing with each other.
Among the leaders in the M&A world. Under the Trump administration, M&A activity is way up due to less regulation. Impeccably well positioned to keep driving forward.
Core holding. Buying today for new clients. For his firm, have to see 10% annualized return over 5 years to justify holding or buying a stock. And this name fits. Stock's not as cheap as 5 years ago, so growth will be slower going forward.
(A Top Pick Dec 22/15. Down 18.41%.) He was hoping that financials moved the market. When there were all those triple digit days back in December, that is usually a point where it is going to go up or come down. In this case the market came down. Financials led the way down. This is no longer a trade. It is probably something you could own here as it is it at very attractive level. No rush to get into this.